Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.34 +0.30 (+1.20%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
37 38 Next >
Align Technology: Protected by more factors than any other stock
Jobs are flowing to the healthcare space, and investment dollars are finding a home in stocks like Align Technology, even the CEO thought it to be the best 
Via MarketBeat
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Generis and Userlane Forge Strategic Partnership to Accelerate Digital Transformation in Regulated Industries
LONDON - Dec. 19, 2023 - PRLog -- Generis and Userlane today announced a strategic partnership. Generis is the developer of the CARA platform for data, content, and business process management in... 
Via PRLog
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
From Pfizer Inc.
Via Business Wire
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Texas Has Given Birth to Its First and Only Global Publicly Traded Cannabis Company, Cannabis Bioscience International Holdings
Houston, Texas--(Newsfile Corp. - December 15, 2023) - On December 5, 2023, Cannabis Bioscience International Holdings (OTC Pink: CBIH) ,... 
Via Newsfile
Topics Cannabis
Quick list of bargain stocks to end the year
Stocks are soaring after a FED dovish pivot, making these value stocks all the more attractive today. Analysts have built up cases as to why they will rally 
Via MarketBeat
Pfizer Declares First-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
The Vaccine Group appoints advisory board in partnering push
Frontier IP Group PLC (AIM:FIPP, OTC:FGPPF) portfolio company The Vaccine Group (TVG) CEO Jeremy Salt speaks to Proactive after announcing that TVG has established an advisory board comprised of what... 
Via TheNewswire.com
Topics Retirement
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Generis and Ideagen Announce Integration to Advance Information Management Processes in Regulated Industries
LONDON - Dec. 13, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Ideagen PleaseReview today announced their integration partnership to... 
Via PRLog
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Pfizer Completes Acquisition of Seagen
From Pfizer Inc.
Via Business Wire
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Pfizer Provides Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
From Pfizer Inc.
Via Business Wire
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
From Pfizer Inc.
Via Business Wire
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
From Pfizer Inc.
Via Business Wire
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Artificial Intelligence
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication 
Via MarketBeat
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
From Pfizer Inc.
Via Business Wire
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... 
Via SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
New Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry
CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the... 
Via PRLog
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.